X4 Pharmaceuticals, Inc
Close on Oct 19, 2026
- Market cap
- $347.45M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $1.77M | $-0.69 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $28.80M | $0.04 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | Before market open | $1.40M | $-0.20 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $600.00K | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $600.00K | $0.45 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | $-0.26 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 4, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 21, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 3, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 4, 2022 | Before market open | – | – | – |
Press releases
Announcements X4 Pharmaceuticals filed with the SEC
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation September 2026 Nasdaq: XFOR EXHIBIT 99.1
Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Closing of
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ABBEY Living with Chronic Neutropenia Driving progress for patients with chronic neutropenic disorders Investor Deck – May 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
X4 Pharmaceuticals Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Enabling a better future for people with rare immune disorders PROGRESS PATIENTS January 2025 Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
3Q 2024 Business Update & Phase 2 Chronic Neutropenia Study Results November 13, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Enabling a better future for people with rare immune disorders PROGRESS PATIENTS May 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105
Material agreement · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and
Results of operations · EX-99.1 to Form 8-K
PROGRESS PATIENTS Investor Call April 29, 2024 EXHIBIT 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Appointment of Industry Veteran
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome
Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results,
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
A Deeper Dive into Mavorixafor Phase 3 Data and Unmet Patient Needs in WHIM Syndrome May 16, 2023 PROGRESS PATIENTS
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial
Results of operations · EX-99.1 to Form 8-K
X4 Pharmaceuticals Announces Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
X4 Pharmaceuticals Prices $65.0 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K